Clinical Trials Logo

Filter by:
NCT ID: NCT04704505 Recruiting - Clinical trials for Prostate Adenocarcinoma

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

BAT-RAD
Start date: April 28, 2022
Phase: Phase 2
Study type: Interventional

This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Previous antiandrogen therapies are permitted, but no more than one (such as abiraterone, enzalutamide, apalutamide, darolutamide). All patients will receive treatment with Radium-223 at a dose of 55 Kilobecquerel (kBq) per kilogram of body weight IV every 28 days, for 6 cycles, plus Testosterone Cypionate 400mg Intramuscular (IM) every 28 days, until progression or unacceptable toxicity.

NCT ID: NCT04703803 Completed - Cancer Clinical Trials

Efficacy of Myofascial Pain Syndrome Treatment in Patients With Cancer in Palliative Care

Start date: August 17, 2020
Phase: Phase 3
Study type: Interventional

Palliative Care is active holistic care offered to people who are in intense suffering related to their health, resulting from a serious life-threatening illness, with a focus on improving the quality of life. Among the symptoms that cause suffering, physical pain has a prominent role in terms of prevalence and impact on well-being, especially in the subgroup of patients with terminal cancer. Myofascial Pain Syndrome may be one of the components of pain in cancer patients in palliative care. However, the literature is scarce in defining the prevalence of this condition in this population, and there is no evidence of the benefit of needling treatment with 1% lidocaine in these patients until now. The objectives of this study are to determinate the prevalence of myofascial pain syndrome and to evaluate the effectiveness of myofascial pain treatment with 1% lidocaine injection in reducing pain in palliative cancer patients, comparing it with a control group in usual care.

NCT ID: NCT04703569 Completed - Venous Ulcers Clinical Trials

Effect of Compressive Therapies on the Healing of Venous Ulcers

VENOS
Start date: December 2, 2020
Phase: N/A
Study type: Interventional

The objective of the study is to compare the effect of two treatments on the healing of venous ulcers in follow-up people in two Primary Health Services, in a city in southern Brazil. The two treatments that will be tested are: (1) the high compression elastic bandage and (2) Unna boot. The two treatments are indicated for the treatment of people with venous insufficiency and who have an active ulcer. The treatment will last 26 weeks (6 months). Once a week, during 26 weeks, a nurse will perform the dressing and will apply the therapy high compression elastic bandage or Unna boot according to a drawing and in every two weeks an evaluator will assess the characteristics of the ulcers and the size.

NCT ID: NCT04703075 Active, not recruiting - Tuberculosis Clinical Trials

Ultra Curto (Ultra Short) TB Prevention Therapy

Start date: March 24, 2022
Phase: Phase 4
Study type: Interventional

To compare treatment success (adherence and completion of treatment) and safety of 1HP with 3HP in HIV-uninfected adults and adolescents at increased risk of TB.

NCT ID: NCT04701684 Recruiting - Stroke, Acute Clinical Trials

WE-TRUST (Workflow Optimization to Reduce Time to Endovascular Reperfusion for Ultra-fast Stroke Treatment)

Start date: June 23, 2021
Phase: N/A
Study type: Interventional

The WE-TRUST study is a multi-center randomized clinical trial to assess the impact of a Direct to Angio Suite (DTAS) workflow on stroke patient outcomes.

NCT ID: NCT04699227 Completed - Covid19 Clinical Trials

Can RIC Prevent Deterioration to Critical Care in Covid19

Start date: January 15, 2021
Phase: N/A
Study type: Interventional

The coronavirus disease (COVID-19) emerged in late 2019 and has since been diagnosed in over a million persons worldwide. As this virus progresses, it causes an extreme and uncontrolled response from the patient's immune system accompanied by reduced oxygen flow to major organs, and subsequent ischaemic injury. The current treatment of COVID-19 is largely supportive without any cure or vaccine available at this time. Developing new methods to reduce this heightened inflammatory response is essential to halting progression of COVID-19 in patients and reducing the severity of damage. The cellular mechanisms seen in COVID-19 are similar to those seen in patients with sepsis. A process known as Remote Ischemic Conditioning (RIC) is an intervention which has been shown to prevent cellular injury including those associated with sepsis. Based on the evidence from studies looking at sepsis, it is anticipated the same benefit would be seen in patients diagnosed with COVID-19. RIC is a simple, non-invasive procedure where a blood pressure cuff is applied to the arm for repeated cycles of inflating and deflating (typically 3-5 cycles of 5 minutes each). This process activates pro-survival mechanisms in the body to protect vital organs and improve the immune system. Therefore, we believe it represents an exciting strategy to protect organs against reduced blood flow and extreme immune response, as seen in COVID-19 infections. This study has already been fully approved

NCT ID: NCT04698811 Completed - Personality Clinical Trials

Virtual Eneagram: Quality of Life, Stress and Anxiety.

Start date: November 18, 2020
Phase: N/A
Study type: Interventional

The objetictive is to observe the influence of the enneagram typology on the perception of anxiety, stress and quality of life through self-knowledge directed in a virtual learning environment. The study is a clinical, primary, analytical, prospective and longitudinal study. It will be carried out in a virtual learning environment (VLE) with the collection of data obtained before and after the beginning of the training on the enneagram. The training will be divided into three online AVA modules. Casuistry: after orientations and signature of the term (Informed Consent Form), they will register on social networks where the initial information will be filled out. to outline the group. Inclusion criteria: participants of both sexes, Brazilians, over 18 years old; agree to sign the Informed Consent Form; with the desire to realize self-knowledge with the availability of time and access to the internet to hold meetings; Non-inclusion criteria: do not have previous information about the enneagram and speak the Portuguese language; Exclusion criteria: participation in work at any time; Individuals who have missed the modules and do not do the replacement later. Instruments: World Health Organization Quality of Life - (WHOQOL-BREF). Stress Perception Scale 10 (EPS-10) The Trait-State Anxiety Inventory: STAI E and T.

NCT ID: NCT04698252 Recruiting - Breast Cancer Clinical Trials

Local Therapy for ER/PR-positive Oligometastatic Breast Cancer

LARA
Start date: April 1, 2021
Phase: Phase 2
Study type: Interventional

Randomized phase 2 trial to evaluate the efficacy of local therapy for oligometastasis from ER/PR-positive breast cancer. The study hypothesis is that local therapy in addition to systemic therapy improves progression-free survival in comparison with systemic therapy alone.

NCT ID: NCT04697628 Active, not recruiting - Cervical Cancer Clinical Trials

Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

innovaTV 301
Start date: February 22, 2021
Phase: Phase 3
Study type: Interventional

This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.

NCT ID: NCT04697615 Completed - Athletes Clinical Trials

Reliability of Algometry in Swimming Athletes

Start date: January 3, 2020
Phase:
Study type: Observational

In the competitive swimming scenario, there is a significant incidence of pain, which can be justified by the high levels of training that exposes athletes to constant stress. In this way, the quantification of pain and its monitoring becomes extremely important for clinical practice. A commonly used tool with easy access and clinical applicability, capable of measuring the pain threshold (PT) in a standardized manner is the pressure algometer. However, there is a shortage in the literature of studies that evaluate the reliability of this instrument in healthy swimming athletes. Objectives: Evaluate the intra and inter-examiner reliability and to describe the profile of the PT measurements measured by the algometer in swimming athletes. Methods: It is a reliability study, and will be composed of fifty young athletes members of swimming teams, of both genders, aged between 12 and 20 years. The evaluation will be carried out on the same day and in 2 steps: (1) Test and (2) Retest. In the first step, through a third examiner, the participants will be subjected to marking of points in pre-determined muscles and in points of referred pain. Next, they will perform the PT assessment through the algometer by two other distinct and trained examiners. The interval between each examiner will be five minutes with the participant at rest. After five minutes the test was performed, the step retest will begin, which will have the same procedures as in the previous step. The statistical package SPSS Statistics 23.0 will be used to conduct the analyzes.